AlphaMadera's AlphaVal page computes Johnson & Johnson's fair value using a multi-method blend (DCF, comparable-multiples, and Graham-style intrinsic value), then compares it to the current market price to flag JNJ as undervalued, fairly valued, or overvalued.

What is Johnson & Johnson's fair value?

Fair value for JNJ is a model output combining discounted cash flow projections, peer-group multiples, and a Graham number floor. The live AlphaVal page shows the blended fair value alongside each method's individual estimate.

How does AlphaMadera value JNJ?

AlphaVal uses three primary techniques: a five-year discounted-cash-flow projection with terminal multiple, peer-group multiple analysis (P/E, EV/EBITDA, P/S), and Graham's defensive-investor intrinsic-value formula. Inputs come from JNJ's most recent reported fundamentals.

JNJ - Johnson & Johnson

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $250.58 DETAILS

AlphaVal

Deterministic, archetype-aware fair value

Stable Earnings Power 80% confidence

Primary model: P/Adj-EPS × Normalized Multiple

Valuation Signal Overvalued Moderate

Trading 17.1% above fair value

Current Price $234.34

Bear Case $171.55 26.8% downside ($171.55 - $234.34) / $234.34 = -26.8% $12.75 × 12x P/E

Fair Value $200.15 14.6% downside ($200.15 - $234.34) / $234.34 = -14.6% $12.75 × 14x P/E

Bull Case $228.74 2.4% downside ($228.74 - $234.34) / $234.34 = -2.4% $12.75 × 16x P/E

Adjust Assumptions

P/E Multiple

14.0x

Adjusted EPS

12.75$

Key Value Driver

Normalized P/E multiple (14x base case)

Implied Market Multiple 18.4x

Plain-Language Summary

Our base-case estimate uses a valuation based on adjusted earnings per share and a normalized price-to-earnings multiple. We then blend that result with the average analyst price target of $250.58 from 40 analysts, using a 30% weight on analyst consensus. That produces an estimated intrinsic value of $200.15 per share.

Warnings

ℹ Dividend-based valuation: $135.71 (below our primary estimate by 24%). Large gaps may signal the dividend doesn't reflect full earning power.

ℹ Wall Street's average price target is $250.58 (from 40 analysts). Our estimate is 29% below the consensus -- consider that gap carefully.

Key Risks

Growth DCF inappropriate — terminal value assumptions dominate
EV/EBITDA misleading for regulated businesses where capex is mandated
Regulatory risk is a fat tail not visible in normal multiples